Editorial commentary: Should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?

Clinical Infectious Diseases

Volumn 55, Issue 2, 2012, Pages 265-267

  Musher, Daniel M ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; ANTIBODY RESPONSE; BACTEREMIA; BACTERIAL COLONIZATION; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; NOTE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

FEMALE; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 84864151046     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis364     Document Type: Note

References (18)

1. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; CD000422.
2. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180: 48-58.
3. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315:1318-27. (Pubitemid 17030409)
4. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103:281-90. (Pubitemid 27459254)
5. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351: 399-403. (Pubitemid 28064163)
6. Musher DM, Mediwala R, Phan HM, Chen G, Baughn RE. Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Clin Infect Dis 2001; 32:534-8. (Pubitemid 32564992)
7. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-55. (Pubitemid 36514705)
8. Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis 2006; 43:1004-8. (Pubitemid 44631100)
9. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, SchlechWF 3rd. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 1986; 104:1-6. (Pubitemid 16182764)
10. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
11. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307:804-12.
12. Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011; 52:633-40.
13. Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008; 46:1093-100. (Pubitemid 351589878)
14. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-8. (Pubitemid 37186212)
15. French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355:2106-11. (Pubitemid 30364659)
16. French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362:812-22.
17. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
18. Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther 2010; 32:1517-32.